PYXS
HealthcarePyxis Oncology, Inc.
$1.21
+$0.06 (+5.22%)
Jan 5, 2026
Price History (1Y)
Analysis
Pyxis Oncology, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $75.34 million. The company operates at a relatively small scale, employing 44 individuals and generating $2.82 million in revenue over the trailing twelve months. The financial health of Pyxis Oncology, Inc. appears to be challenging, with negative profitability metrics. The operating margin stands at -2930.2% and the profit margin is 0.0%. Additionally, the return on equity (ROE) and return on assets (ROA) are both significantly negative, at -87.3% and -34.3%, respectively. From a balance sheet perspective, the company has a significant amount of cash, totaling $76.26 million, but also carries debt of $19.07 million, resulting in a debt to equity ratio of 27.73. Pyxis Oncology, Inc.'s valuation metrics are notable, with a price to sales ratio of 26.72 and an EV/EBITDA of -0.18. The forward P/E ratio is -1.03, indicating that the market expects significant losses in the near term. The company does not pay dividends.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $75.34M
- P/E Ratio
- N/A
- 52-Week High
- $5.55
- 52-Week Low
- $0.83
- Avg Volume
- 1.18M
- Beta
- 1.45
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 44